Autres langues Catalyst Biosciences

Actions

CBIO

US14888D2080

Temps réel estimé Cboe BZX Autres places de cotation 19:15:19 02/05/2024			Varia. 5j.	Varia. 1 janv.
14,36 ^USD	+3,64%		-13,64%	+87,24%

2023	Beijing Continent Pharmaceutical Co. a finalisé l'acquisition de Catalyst Biosciences, Inc. (NasdaqCM:CBIO) dans le cadre d'une opération de fusion inversée.	CI
2023	Catalyst Biosciences, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Catalyst Biosciences : Investor presentation 556.2 KB	11:35
Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K	06/12
Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K	06/11
Catalyst Biosciences : Change in Certifying Accountants - Form 8-K	02/11
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split	30/10/23
Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index	30/10/23
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.	30/10/23
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.	30/10/23
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.	27/10/23
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc	29/08/23
North American Morning Briefing : China Trouble Hits Sentiment	18/08/23
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders	25/07/23
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO	22/07/23
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
North American Morning Briefing : Hopes Build for -3-	15/05/23
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	05/05/23
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	07/04/23
CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	30/03/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Catalyst Biosciences

Actions

CBIO

US14888D2080

Autres langues

Filtres